Tenshi Healthcare Amends Outlook Therapeutics Stake (19th Update)

TL;DR

**Major shareholder Tenshi Healthcare just updated their stake in Outlook Therapeutics.**

AI Summary

Tenshi Healthcare Pte. Ltd. filed an Amendment No. 19 to its Schedule 13D on January 31, 2024, indicating a change in its beneficial ownership of Outlook Therapeutics, Inc. common stock. This amendment updates previous filings regarding Tenshi's significant stake in Outlook Therapeutics, a company focused on biological products. This matters to investors because Tenshi Healthcare Pte. Ltd. is a major shareholder, and changes in their holdings or intentions can signal shifts in confidence or strategic direction for Outlook Therapeutics, potentially impacting the stock price.

Why It Matters

This filing updates the public on a significant shareholder's position, which can influence investor sentiment and potentially signal future strategic moves for Outlook Therapeutics.

Risk Assessment

Risk Level: low — This is an amendment to an existing filing, indicating an update to a known significant shareholder's position rather than a new, unexpected event.

Analyst Insight

Investors should review the full Schedule 13D/A filing to understand the specific changes in Tenshi Healthcare's ownership percentage or stated intentions, as this could provide insight into the future direction or stability of Outlook Therapeutics.

Key Players & Entities

• Tenshi Healthcare Pte. Ltd. (company) — the reporting person and major shareholder of Outlook Therapeutics, Inc.
• Outlook Therapeutics, Inc. (company) — the subject company whose common stock is being reported on
• January 25, 2024 (date) — the date of the event which required the filing of this statement
• Marianne Sarrazin (person) — contact person at Goodwin Procter LLP for Tenshi Healthcare Pte. Ltd.
• $0.01 (dollar_amount) — par value per share of Outlook Therapeutics, Inc. Common Stock

FAQ

Key Financial Figures

• $0.01 — ame of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securiti
• $1,290,131,39 — actions for aggregate gross proceeds of $1,290,131,39 as follows: Date of Transaction Nu
• $0.47720 — ansaction November 28, 2023 100,000 $0.47720 $47,720.00 Open market sale Novembe
• $47,720.00 — November 28, 2023 100,000 $0.47720 $47,720.00 Open market sale November 29, 2023
• $0.48010 — arket sale November 29, 2023 65,044 $0.48010 $31,227.62 Open market sale Novembe
• $31,227.62 — November 29, 2023 65,044 $0.48010 $31,227.62 Open market sale November 29, 2023
• $0.48129 — rket sale November 29, 2023 200,000 $0.48129 $96,258.00 Open market sale Novembe
• $96,258.00 — November 29, 2023 200,000 $0.48129 $96,258.00 Open market sale November 30, 2023
• $0.48036 — rket sale November 30, 2023 167,958 $0.48036 $80,680.30 Open market sale Novembe
• $80,680.30 — November 30, 2023 167,958 $0.48036 $80,680.30 Open market sale November 30, 2023
• $0.48060 — rket sale November 30, 2023 134,956 $0.48060 $64,859.85 Open market sale Decembe
• $64,859.85 — November 30, 2023 134,956 $0.48060 $64,859.85 Open market sale December 1, 2023 6
• $0.48000 — market sale December 1, 2023 61,283 $0.48000 $29,415.84 Open market sale Decembe
• $29,415.84 — e December 1, 2023 61,283 $0.48000 $29,415.84 Open market sale December 5, 2023 3
• $0.45370 — market sale December 5, 2023 34,015 $0.45370 $15,432.61 Open market sale Decembe

Filing Documents

• tm244744d1_sc13da.htm (SC 13D/A) — 79KB
• tm244744d1_ex-1.htm (EX-99.1) — 6KB
• 0001104659-24-008778.txt ( ) — 86KB

of the Schedule

Item 5 of the Schedule 13D is hereby amended and restated in its entirety to read: (a)–(b) The aggregate percentage of Shares reported owned by each Reporting Person named herein is based upon 260,257,517 outstanding Shares, as set forth in the Issuer’s Annual Report on Form 10-K, as amended, filed with the Securities and Exchange Commission on January 24, 2024. A. Tenshi Healthcare (a) As of the date hereof, Tenshi Healthcare directly owns a total of 16,637,024 Shares. This represents approximately 6.4% of the outstanding Shares calculated pursuant to Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the “ Exchange Act ”). (b) 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 16,637,024 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 16,637,024 B. Kumar (a) Kumar is the holder of a controlling interest in Tenshi, which is the sole beneficial owner of Tenshi Healthcare. By virtue of such relationship, Kumar may be deemed to beneficially own 16,637,024 Shares held by Tenshi Healthcare for purposes of Rule 13d-3 under the Exchange Act. This represents approximately 6.4% of the outstanding Shares calculated pursuant to Rule 13d-3 under the Exchange Act. (b) 1. Sole power to vote or direct vote: 0 2. Shared power to vote or direct vote: 16,637,024 3. Sole power to dispose or direct the disposition: 0 4. Shared power to dispose or direct the disposition: 16,637,024 (c) Other than as described in Item 4 (which is incorporated herein by reference), during the past sixty (60) days the Reporting Persons have not effected any transactions in the Shares. (d) Not applicable. (e) Not applicable CUSIP 69012T 206 13D Page 5 of 6 Item 7. Material to be Filed as Exhibits Exhibit Description 1. Joint Filing Agreement, among Tenshi Healthcare Pte. Ltd. and Arun Kumar Pillai dated January 31, 2024 (filed herewith).

Signatures

Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: January 31, 2024 Tenshi Healthcare Pte. Ltd. By: /s/ Lawrence A. Kenyon Name: Lawrence A. Kenyon Title: Attorney-in-Fact Arun Kumar Pillai By: /s/ Lawrence A. Kenyon Name: Lawrence A. Kenyon Title: Attorney-in-Fact

View Full Filing

View this SC 13D/A filing on SEC EDGAR